Where does CytomX Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CytomX Therapeutics, Inc. ranks #4,614 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CytomX Therapeutics, Inc. hold?

CytomX Therapeutics, Inc. holds 76 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is CytomX Therapeutics, Inc.'s Innovation Score?

CytomX Therapeutics, Inc. has an Innovation Score of 44.3 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CytomX Therapeutics, Inc. focus on?

CytomX Therapeutics, Inc.'s top technology area is C07K (Peptides) with 75 patents, ranking #109 of 3,615 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is CytomX Therapeutics, Inc.'s patent grant rate increasing or decreasing?

CytomX Therapeutics, Inc.'s recent grant velocity is +47% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for CytomX Therapeutics, Inc.'s patents?

CytomX Therapeutics, Inc.'s patents average 31.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CytomX Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CytomX Therapeutics, Inc.

USPTO PatentsView assignee record - 76 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cytomx ranks #4,614 of 49,997 tracked US assignees by granted-patent volume, with 76 patents across 7 technology areas.

#4,614
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.3/100): 31.7
avg claims per patent: +47%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4614 · US Corporation #4,614 · 76 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 76 grants
TOP-DECILE #4,614/49,997
PHOTO-FINISH Coherus BioSciences
CPC-NARROW C07K · 7 areas
INNOV-PAR 44.3/100
CLAIMS-DENSE 31.7 claims/avg
TYPE-USCORP US Corporation
VEL-UP +47% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Coherus BioSciences, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cytomx’s 44.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 15.0 pts (34%) Velocity 4.9 pts (11%) Breadth 9.4 pts (21%) Claim depth 15.0 pts (34%)

Qualcomm Incorporated · highest

85
Arteris · near

44
Automatic Bar Controls · near

44
CytomX Therapeutics · this assignee

44
Ericsson AB · near

44
Zodiac Aerotechnics · near

44
3D Lighting… · lowest

7

What this shows Cytomx's Innovation Score is 44.3/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cytomx?

Each dot is one of Cytomx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cytomx’s own 31.7 claims/patent is ABOVE the 8.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cytomx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cytomx's grants concentrate

CytomX Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 98.7% of grants classified under C07K (Peptides). Peak complete grant year is 2021 (12 grants) versus a trough of 4 in 2015. By volume, Cytomx sits between Coherus BioSciences, Inc. and Digilock Asia Ltd.

Cytomx's three-year grant acceleration

From 2019–2021 to 2022–2024, CytomX Therapeutics, Inc. moved from 30 to 22 grants (0.73x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Coherus Bioscienc…

76
Conformis

76
Cricut

76
Crimson Trace

76
Danfoss Power Sol…

76
DMF

76
DMG Mori Seiki

76
Digilock Asia

76
Cytomx Therapeuti… ◀

76

What this shows CytomX holds 76 patents at rank #4,614, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CytomX

By rank, the assignees closest to #4,614 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in CytomX's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for CytomX, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), CytomX ranks #109 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Arteris, Inc. 44 Zodiac Aerotechnics 44 Automatic Bar Controls, Inc. 44 Ericsson AB 44

Similar claim depth

Nearest assignees by average claims per patent (31.7 here).

Federal Express Corporation 31.8 avg D5ai LLC 31.8 avg OVD Kinegram AG 31.5 avg ThermoChem Recovery International, Inc. 32.1 avg

Cytomx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

CytomX Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	5.3%
2016	5	6.6%
2017	7	9.2%
2018	6	7.9%
2019	8	10.5%
2020	10	13.2%
2021	12	15.8%
2022	6	7.9%
2023	6	7.9%
2024	10	13.2%
2025partial year	2	2.6%

Which technologies does CytomX Therapeutics, Inc. patent most?

C07K - Peptides 75

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 57

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 54

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 27

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 16

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 4

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CytomX Therapeutics, Inc.'s patent record in context - here's where to go next.

CytomX Therapeutics, Inc.'s lead technology class is C07K (Peptides), 98.7% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #4,614 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CytomX Therapeutics, Inc. against Coherus BioSciences, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.